OurMBCLife(@ourmbclife) 's Twitter Profile Photo

Our senior producer and host Lynda Weatherby shares how living with can be terrifying. Our podcast is here to help. We have broached the subject of brain mets with clinicians and patients.
➡️ Click the link buff.ly/3Kf7BYv for eps on this subject

account_circle
Teresa Amaral, MD, PhD(@TeresaSAmaral) 's Twitter Profile Photo

Attending ?
Here is why U should come 2 & other track sessions.
Exciting data in & setting -MelSM &
I am looking forward to seeing friends & colleagues, & discussing with impact on pts care!

account_circle
AstraZenecaUS(@AstraZenecaUS) 's Twitter Profile Photo

Tune into to hear late-breaking exploratory data from the FLAURA2 Phase III trial, which demonstrated positive results for people living with and . Learn more about the results: bit.ly/3M9VXzd

account_circle
Anastasia Janas(@AnastasiaJanas) 's Twitter Profile Photo

📍In Berlin? Join in to learn about with the amazing Mariam Aboian! Uncover its core principles & get to know success stories like BraTS!
🗓️ Fri, Oct 27, 4:45 pm CET
Don't miss it! 🚀

📍In Berlin? Join in to learn about #OpenScience with the amazing @MariamAboian!  Uncover its core principles & get to know success stories like @BraTS_challenge!
🗓️ Fri, Oct 27, 4:45 pm CET
Don't miss it! 🚀 #BrainMets #ImagineQuant
account_circle
MSK CME(@MSKCME) 's Twitter Profile Photo

What is new in diagnosis? Join leading experts in both non-invasive liquid biopsy & molecular imaging on 3/7 to discuss what is next in the early detection of . Registration is complimentary: bit.ly/BrainMets2024

Nelson Moss

account_circle
Amanda Van Swearingen, PhD(@DrVanSwearingen) 's Twitter Profile Photo

HER2CLIMB-02 results in population. Improved PFS and ORR with adding tucatinib to T-DM1. Continued evidence that tucatinib is an option for patients with CNS Mets. And highlighting importance of trials specifically for patients with , like BRIDGET! Duke Center for Brain and Spine Metastasis

HER2CLIMB-02 results in #brainmets population. Improved PFS and ORR with adding tucatinib to T-DM1. Continued evidence that tucatinib is an option for patients with CNS Mets. And highlighting importance of trials specifically for patients with #brainmets, like BRIDGET! @DukeMets
account_circle
Weijie (Mark) Ma(@markma666666) 's Twitter Profile Photo

Happy to share our latest 23-page comprehensive review in IJMS (IF: 5.6) on NSCLC brain metastases & biomarkers. A. Aziz Ould Ismail Dartmouth Health Pathology Residency. As the corresponding author, I'm grateful for this collaborative effort. 📣📣
rb.gy/y3jvkj

Happy to share our latest 23-page comprehensive review in IJMS (IF: 5.6) on NSCLC brain metastases & biomarkers.#NSCLC #BrainMets #Biomarkers #TME  @AzizOuldIsmail @DHPathRes. As the corresponding author, I'm grateful for this collaborative effort. 📣📣
rb.gy/y3jvkj
account_circle
Rituraj Upadhyay, MD(@aiims2738) 's Twitter Profile Photo

Woke up to this! Thank you QuadShot News for featuring us. Really an amazing summary of the paper. Kudos to the writer(s). I’m guessing triple threat is for 3-fraction SRS? May just steal this for our next paper lol.

Joshua D. Palmer, MD Raju Raval, MD DPhil

Woke up to this! Thank you @QuadShotNews for featuring us. Really an amazing summary of the paper. Kudos to the writer(s). I’m guessing triple threat is for 3-fraction SRS? May just steal this for our next paper lol.

@joshuapalmermd @DrRajuRaval 

#radonc #brainmets #srs #ntcp
account_circle
Dana-Farber’s Breast Oncology Center(@DFCI_BreastOnc) 's Twitter Profile Photo

MBCBrainMets.org recently featured clinical trials, including our phase II trial for . Watch the video below to learn more about this new and exciting Dana-Farber research 👇👇👇
mbcbrainmets.org/featured-clini…

MBCBrainMets.org recently featured #BrainMets clinical trials, including our phase II #DATOBase trial for #BreastCancerBrainMetastases.  Watch the video below to learn more about this new and exciting @DanaFarber research 👇👇👇
mbcbrainmets.org/featured-clini…
account_circle